NCT07698535

Brief Summary

This clinical trial studies whether measuring circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction (TF) can be used to help guide the early stopping (discontinuation) of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) in patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Many types of tumors tend to lose cells or release different types of cellular products including their deoxyribonucleic acid, which is referred to as ctDNA, into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for the disease to grow, spread, or get worse or come back after a period of improvement. ctDNA TF is a type of ctDNA measurement. Research has shown ctDNA TF may be a promising way to predict which patients will respond to 177Lu-PSMA-617 treatment. Measuring ctDNA TF may help doctors identify which patients may benefit from changing treatments sooner, which may be an effective way to guide early 177Lu-PSMA-617 treatment discontinuation in patients with metastatic castration-resistant prostate cancer.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P50-P75 for phase_2

Timeline
32mo left

Started Dec 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 25, 2026

Completed
18 days until next milestone

First Posted

Study publicly available on registry

July 13, 2026

Completed
5 months until next milestone

Study Start

First participant enrolled

December 1, 2026

Expected
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 5, 2029

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 5, 2029

Last Updated

July 17, 2026

Status Verified

July 1, 2026

Enrollment Period

2.6 years

First QC Date

June 25, 2026

Last Update Submit

July 15, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Number and proportion among those recruited with detectable circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction who undergo randomization

    Will be analyzed descriptively. Among patients who initiate lutetium Lu 177 vipivotide tetraxetan and undergo cycle (C) 2 day (D) 1 ctDNA tumor fraction assessment, the number (and proportion among those recruited) with detectable ctDNA tumor fraction who undergo randomization will be reported with a two-sided 95% Wilson confidence interval.

    Up to 2 cycles (Cycle length = 6 weeks)

  • Number of patients screened, enrolled, evaluable for C2D1 ctDNA tumor fraction and for who cycle 3 is administered

    Will report the number of patients screened, enrolled, evaluable for C2D1 (week 13) ctDNA tumor fraction, classified as having detectable versus undetectable ctDNA tumor fraction, and for who cycle 3 is administered. Reasons for failure to undergo C1D28 ctDNA assessment or randomization will be tabulated.

    Up to cycle 3 administration (Cycle length = 6 weeks)

Secondary Outcomes (5)

  • Radiographic progression free survival (PFS)

    From randomization to disease progression, clinical progression, or death, whichever occurs first, assessed up to 1 year

  • Overall survival

    From the start of treatment until death from any cause, assessed up to 1 year

  • Prostate-specific antigen (PSA) PFS

    From the start of treatment until PSA progression, assessed up to 1 year

  • Proportion of patients with a ≥ 50% decline in PSA from baseline (PSA50) response rate

    Up to 1 year

  • Duration of response

    From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 1 year

Study Arms (3)

Cycles 1 and 2 (177Lu-PSMA-617, ctDNA testing)

OTHER

Patients receive 177Lu-PSMA-617 IV over 20-30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection with ctDNA TF testing at baseline and C2D1. Patients with undetectable ctDNA TF (\< 3%) on C2D1 continue to receive 177Lu-PSMA-617 as above in the absence of disease progression or unacceptable toxicity. Patients with detectable ctDNA TF (≥ 3%) on C2D1 are randomized to 1 of 2 arms. Additionally, patients undergo PSMA PET during screening, SPECT/CT on study, and additional blood sample collection as well as CT throughout the study.

Drug: Lutetium Lu 177 Vipivotide TetraxetanProcedure: Cell-free Circulating Tumor DNA AssayProcedure: Computed TomographyProcedure: PSMA PET ScanProcedure: Single Photon Tomography and Computed Tomography ScanProcedure: Biospecimen Collection

Cycle 3+ Arm I (177Lu-PSMA-617)

ACTIVE COMPARATOR

Starting with cycle 3, patients receive 177Lu-PSMA-617 IV over 20-30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo PSMA PET during screening, SPECT/CT on study, and additional blood sample collection as well as CT throughout the study.

Drug: Lutetium Lu 177 Vipivotide TetraxetanProcedure: Computed TomographyProcedure: PSMA PET ScanProcedure: Single Photon Tomography and Computed Tomography ScanProcedure: Biospecimen Collection

Cycle 3+ Arm II (docetaxel)

ACTIVE COMPARATOR

Starting with cycle 3, patients receive docetaxel IV on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo PSMA PET during screening, SPECT/CT on study, and additional blood sample collection as well as CT throughout the study.

Procedure: Computed TomographyDrug: DocetaxelProcedure: PSMA PET ScanProcedure: Single Photon Tomography and Computed Tomography ScanProcedure: Biospecimen Collection

Interventions

Given IV

Also known as: 177Lu-labeled PSMA-617, 177Lu-PSMA-617, Pluvicto, AAA 617, AAA-617, AAA617, Lu177-PSMA-617, Lutetium Lu 177-PSMA-617, Lutetium-177-PSMA-617
Cycle 3+ Arm I (177Lu-PSMA-617)Cycles 1 and 2 (177Lu-PSMA-617, ctDNA testing)

Undergo ctDNA TF testing

Also known as: ctDNA Assay, Signatera
Cycles 1 and 2 (177Lu-PSMA-617, ctDNA testing)

Undergo CT

Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography
Cycle 3+ Arm I (177Lu-PSMA-617)Cycle 3+ Arm II (docetaxel)Cycles 1 and 2 (177Lu-PSMA-617, ctDNA testing)

Given IV

Also known as: Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate
Cycle 3+ Arm II (docetaxel)
PSMA PET ScanPROCEDURE

Undergo PSMA PET

Also known as: Prostate-specific Membrane Antigen PET, PSMA PET, PSMA-Positron emission tomography
Cycle 3+ Arm I (177Lu-PSMA-617)Cycle 3+ Arm II (docetaxel)Cycles 1 and 2 (177Lu-PSMA-617, ctDNA testing)

Undergo SPECT/CT

Also known as: SPECT/CT, SPECT/CT SCAN
Cycle 3+ Arm I (177Lu-PSMA-617)Cycle 3+ Arm II (docetaxel)Cycles 1 and 2 (177Lu-PSMA-617, ctDNA testing)

Undergo blood sample collection

Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Cycle 3+ Arm I (177Lu-PSMA-617)Cycle 3+ Arm II (docetaxel)Cycles 1 and 2 (177Lu-PSMA-617, ctDNA testing)

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Willing and able to provide informed consent
  • Adult males ≥ 18 years age
  • History of histologically confirmed adenocarcinoma of the prostate without evidence of neuroendocrine or small cell differentiation. If histology is not available, patients must have metastatic disease typical of prostate cancer (i.e., involving bone or pelvic lymph nodes or para-aortic lymph nodes)
  • Evidence of metastatic disease on bone scan or CT scan
  • Patient must have evidence of castration- resistant prostate cancer as evidenced by PSA progression (per Prostate Cancer Working Group 3 \[PCWG3\] criteria) and a castrate serum testosterone level (i.e., ≤ 50 mg/dL)
  • Serum/plasma PSA progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal start value is 2.0 ng/mL
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Prior treatment and progression on at least one androgen receptor pathway inhibitor (ARPI), in either castration-sensitive or castration-resistant setting
  • Eligible for treatment with either 177Lu-PSMA-617 or docetaxel as per their respective Food and Drug Administration (FDA) labels
  • Absolute neutrophil count ≥ 1.5 x 10\^9/L
  • Platelet count ≥ 100 x 10\^9/L
  • Hemoglobin ≥ 9 g/dL
  • Creatinine clearance ≥ 50 ml/min (calculated by Cockcroft-Gault formula)
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) except for patients with known Gilbert's syndrome (direct bilirubin ≤ 1.5 x ULN)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN, unless liver metastases are present in which case they must be ≤ 5 x ULN. For patients with known Gilbert's Syndrome they must be ≤ 3 x ULN
  • +1 more criteria

You may not qualify if:

  • Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition that could interfere with patient safety or provision of informed consent to participate in this study
  • Evidence of metastatic neuroendocrine/small cell prostate cancer (NEPC). Note: baseline biopsy is not required
  • Patients receiving any systemic therapy (aside from a luteinizing hormone-releasing hormone \[LHRH\] analogue) or radiotherapy within 2 weeks prior to study treatment
  • Persistent toxicities (CTCAE grade \> 2) from prior cancer therapy, excluding alopecia and stable neuropathy
  • Patients considered a poor medical risk due to a serious, uncontrolled medical disorder or active, uncontrolled infection. Examples include, but are not limited to uncontrolled seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent
  • Patients who are known to be serologically positive for human immunodeficiency virus (HIV) and a CD4 count \< 200
  • Patients with known active hepatitis (i.e. hepatitis B or C). Prior hepatitis C infection is allowed as long as polymerase chain reaction (PCR) is negative
  • Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
  • Serious cardiac disorder, including but not limited to uncontrolled ventricular arrhythmia, recent (within 12 months) myocardial infarction, resting electrocardiogram (ECG) indicating Fridericia's corrected QT interval prolongation \> 500ms, or congenital long QT syndrome
  • Prior systemic chemotherapy with taxane chemotherapy, including in hormone sensitive setting (e.g. docetaxel or cabazitaxel)
  • Brain metastases or active epidural disease (treated epidural disease is permitted)
  • Note: baseline brain imaging is not required
  • Contraindication to prednisone therapy including poorly controlled diabetes mellitus

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

PluvictoDocetaxelGlutamate Carboxypeptidase IISpecimen Handling

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

TaxoidsCyclodecanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsDiterpenesTerpenesCarboxypeptidasesExopeptidasesPeptide HydrolasesHydrolasesEnzymesEnzymes and CoenzymesMetalloexopeptidasesMetalloproteasesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative Techniques

Study Officials

  • Michael Schweizer, MD

    Fred Hutch/University of Washington Cancer Consortium

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Michael Schweizer, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 25, 2026

First Posted

July 13, 2026

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

July 5, 2029

Study Completion (Estimated)

July 5, 2029

Last Updated

July 17, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share

Locations